755 related articles for article (PubMed ID: 25572407)
1. Considerations in the early development of biosimilar products.
Li EC; Abbas R; Jacobs IA; Yin D
Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
[TBL] [Abstract][Full Text] [Related]
2. Key considerations in the preclinical development of biosimilars.
Bui LA; Hurst S; Finch GL; Ingram B; Jacobs IA; Kirchhoff CF; Ng CK; Ryan AM
Drug Discov Today; 2015 May; 20 Suppl 1():3-15. PubMed ID: 25912284
[TBL] [Abstract][Full Text] [Related]
3. Biosimilar safety factors in clinical practice.
Reinisch W; Smolen J
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
[TBL] [Abstract][Full Text] [Related]
4. Development of biosimilars.
Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
6. Clinical data and regulatory issues of biosimilar products.
Stevenson JG
Am J Manag Care; 2015 Dec; 21(16 Suppl):s320-30. PubMed ID: 26788808
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Gonçalves J; Araújo F; Cutolo M; Fonseca JE
Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars: Rationale and current regulatory landscape.
Olech E
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
[TBL] [Abstract][Full Text] [Related]
9. Clinical development and trial design of biosimilar products: a Japanese perspective.
Nagasaki M; Ando Y
J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars battle rages on, Amgen fights both sides.
Senior M
Nat Biotechnol; 2013 Apr; 31(4):269-70. PubMed ID: 23563402
[No Abstract] [Full Text] [Related]
11. [Regulatory aspects of biosimilars. Myths and facts].
Schneider CK; Weise M
Z Rheumatol; 2015 Oct; 74(8):695-700. PubMed ID: 26385104
[TBL] [Abstract][Full Text] [Related]
12. Global regulatory standards for the approval of biosimilars.
Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
[TBL] [Abstract][Full Text] [Related]
13. Biosimilar insulins.
Heinemann L
Expert Opin Biol Ther; 2012 Aug; 12(8):1009-16. PubMed ID: 22583127
[TBL] [Abstract][Full Text] [Related]
14. Differentiating biosimilarity and comparability in biotherapeutics.
Azevedo V; Hassett B; Fonseca JE; Atsumi T; Coindreau J; Jacobs I; Mahgoub E; O'Brien J; Singh E; Vicik S; Fitzpatrick B
Clin Rheumatol; 2016 Dec; 35(12):2877-2886. PubMed ID: 27734233
[TBL] [Abstract][Full Text] [Related]
15. Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development.
Cai XY; Thomas J; Cullen C; Gouty D
Bioanalysis; 2012 Sep; 4(17):2169-77. PubMed ID: 23013399
[TBL] [Abstract][Full Text] [Related]
16. A consistency approach for evaluation of biosimilar products.
Tsou HH; Chang WJ; Hwang WS; Lai YH
J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
[TBL] [Abstract][Full Text] [Related]
17. Analytic characterization of biosimilars.
Sullivan PM; DiGrazia LM
Am J Health Syst Pharm; 2017 Apr; 74(8):568-579. PubMed ID: 28389456
[TBL] [Abstract][Full Text] [Related]
18. Low-molecular-weight heparin biosimilars: potential implications for clinical practice. Australian Low-Molecular-Weight Heparin Biosimilar Working Group (ALBW).
Nandurkar H; Chong B; Salem H; Gallus A; Ferro V; McKinnon R;
Intern Med J; 2014 May; 44(5):497-500. PubMed ID: 24816308
[TBL] [Abstract][Full Text] [Related]
19. Considerations related to comparative clinical studies for biosimilars.
Rathore AS; Stevenson JG; Chhabra H
Expert Opin Drug Saf; 2021 Mar; 20(3):265-274. PubMed ID: 33455482
[No Abstract] [Full Text] [Related]
20. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
Falit BP; Singh SC; Brennan TA
Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
